Press Releases Year None2020201920182017 March 24, 2020 Prevail Therapeutics Receives U.S. FDA Fast Track Designation for PR006 to Slow the Progression of Frontotemporal Dementia with a GRN Mutation March 3, 2020 Prevail Therapeutics Provides Clinical Advancement Update on PR001 for the Treatment of Parkinson’s Disease with GBA1 mutations March 2, 2020 Prevail Therapeutics Announces Investigational New Drug Application Active for PR006 for the Treatment of Frontotemporal Dementia with GRN Mutation February 21, 2020 Prevail Therapeutics to Present at Upcoming Conferences February 12, 2020 Prevail Therapeutics’ PR001 Receives Orphan Drug Designation and Rare Pediatric Disease Designation from FDA February 6, 2020 Prevail Announces Presentations at the 16th Annual WORLDSymposium™ 2020 January 9, 2020 Prevail Therapeutics Provides PR001 Program Update Pagination First page « first Previous page ‹ previous Page 1 Current page 2 Displaying 11 - 17 of 17
